VATupdate
VAT

Share this post on

Decentralized Clinical Trials: Data Considerations & Value-Added Taxes

By Salman Shah and Nick Davies, Ernst & Young LLP

Clinical trials are critical to life sciences innovation, providing the indispensable framework for developing new medicines and validating their effectiveness. But the rapidly changing regulatory, tax, and global business landscape, driven in part by COVID-19 and ongoing economic and political shifts, means that biopharma executives must keep careful watch over how they implement and monitor decentralized clinical trials (DCTs). As industry leaders face looming losses of exclusivity and the need to replenish the therapeutic pipeline, the successful execution of DCTs is paramount.

There are several best practices for DCT administration in the current landscape. Below, we outline key considerations for biopharma executives in overseeing hybrid or fully decentralized clinical trials.

Source: clinicalleader.com

Sponsors:

VAT news
VAT news

Advertisements:

  • VATupdate.com